Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi

NEW YORK--(BUSINESS WIRE)--Dec. 29, 2020-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted a New Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news